Results from a phase 1/2 clinical trial (NCT05099172) show the safety and efficacy of sevabertinib (BAY2927088) in patients ...

Amtagvi monotherapy achieved a 25.6% objective response rate and 71.8% disease control rate in NSCLC patients without ...

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical ...

Last month, IceCure Medical’s tumor-freezing technology won FDA approval for treating early-stage breast cancer. Now, the Israel-based medtech is touting a new study showing its procedure combined ...

5-year overall survival (OS) rate for stereotactic body radiation ... body radiation therapy plus cryoablation using liquid nitrogen for stage I non-small cell lung cancer with tumors =2 cm" in the ...

October brought several updates in the lung cancer field, ranging from notable trial results to patient-centered perspectives ...

Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif., Nov ...

According to the latest statistics from the Ministry of Data and Statistics, 21.9% of cancer-related deaths are attributed to ...

Hutchmed China said in an update on Wednesday that it has completed patient enrollment for its global phase three ‘Saffron’ trial evaluating the combination of Orpathys and Tagrisso in certain lung ...

ICIs are safe and effective for HIV-positive NSCLC patients, with no significant differences in survival outcomes compared to ...

After beating lung cancer, a Cleveland Clinic employee shares his story with patients facing their own health battles.

Treatment innovations in advanced lung cancer and melanoma over the past 2 decades have significantly improved OS, but they ...